Onco Exam 3 schiff moa/ta/ae

  1. MOA: inhibitor of enzyme mTOR by binding to intracellular protein FKBP-12; results in G1 growth arrest

    TA: renal cell carcinoma, mantle cell lymphoma (off label)

    SE: hyperlipidemia and hyperglycemia
  2. MOA: inhibitor of enzyme mTOR by binding to intracellular protein FKBP-12; results in G1 growth arrest

    TA: renal cell carcinoma; pancreatic neuroendocrine tumors; oral treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis; postmenopausal, HER2- breast cancer in combo with exemestane

    AE: none
  3. MOA: bind to alpha-beta tubulin heterodimer on microtubules to stabilize them and block metaphase leading to apoptosis

    TA: breast cancer, endometiral cancer (unlabeled), can be combined with capecitabine

    AE: sensory peripheral neuropathies
  4. MOA: inhibit microtubule by binding to tubulin and arresting mitosis in metaphase

    TA: gel for anogenital and perianal warts (condyloma acuminata warts)

    AE: significant neuropathies and death if applied to multiple and widespread lesions
  5. MOA: complexes with topoisomerase II to produce ds-dna breaks (G2 phase)

    TA: refractory testicular tumor, SCLC

    AE: none; inc risk of secondary malignancies within 5-8 yrs
  6. MOA: complexes with topoisomerase II to produce ds-dna breaks (G2 phase)

    TA: childhood acute lymphoblastic leukemia (ALL); adult ALL and NHL (off label)

    AE: none
  7. MOA:intercalates with DNA forming adducts that act as alkylating agents when light activated

    TA: repigmentation of idiopathic vitiligo (leukoderma); psoriasis nonresponsive to other therapies; cutaneous t-cell lymphoma; cervical dysplasia

    AE: severe burns and blistering if post UVA light exposure too soon after therapy
  8. MOA: activates protein kinase isoforms, inducing apoptosis

    TA: short course topical therapy of actinic keratosis; precancerous skin lesions (topical)

    AE: erythema, peeling, crusting, irritation
  9. MOA: unknown, not cytolytic; induces maturation of acute promyelocytic leukemia cells in culture

    TA: induction of remission in pts with acute promyelocytic leukemia (APL)

    AE: effects associated with high doses of Vit A (headache, fever, dryness); rapid leukocytosis, CV/resp multiorgan failure (Retinoic acid-APL syndrome)
  10. MOA: modulates innate and adaptive immune response by suppressing leukocyte recruitment and t cell activation

    TA: cutaneous lesions in pts with AIDS-related Kaposi's sarcoma; cutaneous T-cell lymphoma

    AE: erythema/rash, burning pain, pruritus
  11. MOA: binds and activates retinoid x receptor subtypes activating receptors that function as transcription factors to regulate cel differentiation and proliferation

    TA: cutaneous t-cell lymphoma

    AE: hyperlipid, hyperchol, hypothyroid
  12. MOA: photochemical elevation to excited state by laser light leads to radical initial and ischemic necrosis within tumor secondary to vascular occlusion - thromboxane A2

    TA: photodynamic therapy in esophageal cancer, endobroncial NSCLC, Barrett's esophagus

    AE: Many (CV, CNS, GI, Resp)
    Porfimer sodium
  13. MOA: transition state inhibition of adenosine deminase, inhibiting ribonucleotide reductase; antimetabolite

    TA: hairy cell leukemia

    AE: neurologic (nervousness, insomnia, depression, hallucinations)
  14. MOA: inhibits growth of malignant cells that are asparagine-dependent

    TA: pediatric acute lymphocytic leukemia

    AE: decreased Vit K dependent clotting factors leading to hemorrhage; hypersensitivity
  15. MOA: induces differention of APL cells by degrading PML-RAR alpha protein; induces apoptosis; inhibits angiogenesis

    TA: induction of remission and consolidation of acute promyelocytic leukemia

    AE: prolong QT interval, APL differentiation syndrome (rash, dyspnea, fluid retention, pleural or pericardial effusions); leukocytosis
    Arsenic trioxide
  16. MOA: binds to tubulin at the rhizoxin binding site to inhibit microtubule assembly, induce microtubule disassembly, disrupt mitosis

    TA: combined with trastuzumab as T-DM1 in treatment of Her2+ breast cancer

    AE: none listed
Card Set
Onco Exam 3 schiff moa/ta/ae